The effect of hydroxyurea on vasculopathy in a child with sickle cell disease.
We report serial CNS findings in a girl with sickle cell disease and stroke. Religious considerations precluded transfusion and bone marrow transplantation; therefore, she received single-agent hydroxyurea therapy for almost 6 years. MR angiography showed that vascular patency improved, although diffuse cerebral atrophy slowly worsened. Hydroxyurea can be effective in treating vasculopathy, but it might not prevent the progression of parenchymal damage in advanced disease.
Helton
Kathleen J
KJ
Department of Diagnostic Imaging, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
Wang
Winfred C
WC
Wynn
Lynn W
LW
Khan
Raja B
RB
Steen
R Grant
RG
D000986:Antisickling Agents / Q000627:therapeutic use*; D001921:Brain / Q000000981:diagnostic imaging / Q000378:metabolism / Q000503:physiopathology; D002648:Child; D003131:Combined Modality Therapy; D018450:Disease Progression; D005260:Female; D005319:Fetal Hemoglobin / Q000187:drug effects / Q000378:metabolism; D006450:Hemoglobin SC Disease / Q000150:complications / Q000517:prevention & control* / Q000601:surgery*; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use*; D018810:Magnetic Resonance Angiography; D011859:Radiography; D020521:Stroke / Q000188:drug therapy / Q000209:etiology / Q000601:surgery; D014652:Vascular Diseases / Q000150:complications / Q000517:prevention & control*; D014654:Vascular Patency / Q000187:drug effects / Q000502:physiology
D000986:Antisickling Agents; D005319:Fetal Hemoglobin; D006918:Hydroxyurea